Intangible Assets

12 Months Ended

Dec. 31, 2025

Intangible Assets [Abstract]

INTANGIBLE ASSETS

NOTE 5 – INTANGIBLE ASSETS

Intangible assets represent the cost of medical formulas approved for production by the NMPA, the intellectual property acquired from Chengdu Bonier Medical Technology Development Co., Ltd. through certain Technology Transfer Agreement (“Bonier Agreement”) and the invention patents and intellectual property acquired pursuant to Technology Transfer Agreements. No costs were reclassified from advances to intangible assets during the years ended December 31, 2025 and 2024, respectively.

On December 22, 2025, the Company entered into a Technology Transfer Agreement (the “Zhang Agreement”) with Juan Zhang (“Transferor Zhang”). Transferor Zhang owns an invention patent of an Ipragliflozin tablets and Method for Its Preparation. Pursuant to the Agreement, Transferor Zhang will transfer the ownership of the patent to Helpson. Transferor Zhang or its designated third party shall provide relevant technical services, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services.

The aggregate transfer price as contemplated by the Zhang Agreement is $9.66 million which was paid to the Transferor and his four designees upon the issuance of 7,000,000 shares of common stock of the Company at $1.38 per share based on the closing market price of the Company’s common stock on the acquisition date of the intangible asset.  The Company recorded the amount as intangible assets on the accompanying balance sheet as of the closing date.

On December 4, 2025, the Company entered into a Technology Transfer Agreement the (“Lijie Tang Agreement”) with Lijie Tang (“Transferor Tang”) Transferor Tang owns an invention patent of a Captopril microcapsule and Method for Its Preparation. The seller or its designated third party shall provide relevant technical services, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services.

The aggregate transfer price as contemplated by the Lijie Tang Agreement Agreement is $5.81 million which was paid to the Transferor upon the issuance of 3,500,000 shares of common stock of the Company at $1.66 per share based on the closing market price of the Company’s common stock on the acquisition date of the intangible asset.  The Company recorded the amount as intangible assets on the accompanying balance sheet as of the closing date.

On August 29, 2025, the Company entered into a Technology Transfer Agreement (the “Yan Yang Agreement”) with Yan Yang (“Transferor Yang”). Transferor Yang owns an Apremilast Vector and method for its preparation, which has obtained a patent for the treatment of chronic obstructive pulmonary disease (the “Liu Invention Patent”). Pursuant to the Tao Liu Agreement, Transferor Yang will transfer the ownership of the Yang Invention Patent to Helpson. Transferor Yang or his designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services.

The aggregate transfer price as contemplated by the Yan Yang Agreement is $2.446 million which was paid to the Transferor and his two designees upon the issuance of 1,760,000 shares of common stock of the Company at $1.39 per share based on the closing market price of the Company’s common stock as of the closing date.  The Company recorded the amount as intangible assets on the accompanying balance sheet on the acquisition date of the intangible asset. The value of the intangible asset will be amortized over its remaining useful life of approximately 15.5 years.

On November 22, 2024, Helpson entered into a Technology Transfer Agreement (the “Li Yong Agreement”) with Li Yong (“Transferor Yong”). Transferor Yong owns an invention patent of a pharmaceutical composition for treatment of psoriatic arthritis and moderate to severe plaque psoriasis (the “Yong Invention Patent”). Pursuant to the Li Yong Agreement, Transferor Yong will transfer the ownership of the Yong Invention Patent to Helpson.

The aggregate transfer price as contemplated by the Agreement is $580,000 which was paid to the Transferor and his two designees upon the issuance of 2,900,000 shares of common stock of the Company at $0.20 per share based on the closing market price of the Company’s common stock as of the closing date of December 2, 2024.  The Company recorded the amount as intangible assets on the accompanying balance sheet as of the closing date. 

On November 22, 2024, Helpson entered into a Technology Transfer Agreement (the “Zhao Xijun Agreement”) with Zhao Xijun (“Transferor Xijun”). Transferor Xijun owns an invention patent of a riboflavin stomach floating tablet and a preparation method thereof (the “Xijun Invention Patent”). Pursuant to the Li Yong Agreement, Transferor Yong will transfer the ownership of the Xijun Invention Patent to Helpson and provide relevant technical services.

The aggregate transfer price as contemplated by the Agreement is $580,000 which was paid to the Transferor and his two designees upon the issuance of 2,900,000 shares of common stock of the Company at $0.20 per share based on the closing market price of the Company’s common stock as of the closing date of December 2, 2024.  The Company recorded the amount as intangible assets on the accompanying balance sheet as of the closing date.

On November 22, 2024, Helpson entered into a Technology Transfer Agreement (the “Zhao Chunhai Agreement”) with Zhao Chunhai (“Transferor Chunhai”). Transferor Chunhai owns an invention patent of a pharmaceutical composition for the treatment of gray nail (the “Chunhai Invention Patent”). Pursuant to the Zhao Chunhai Agreement, Transferor Chunhai will transfer the ownership of the Chunhai Invention Patent to Helpson and provide relevant technical services.

The aggregate transfer price as contemplated by the Agreement is $600,000 which was paid to the Transferor and his two designees upon the issuance of 3,000,000 shares of common stock of the Company at $0.20 per share based on the closing market price of the Company’s common stock as of the closing date of December 2, 2024.  The Company recorded the amount as intangible assets on the accompanying balance sheet as of the closing date. 

On November 22, 2024, Helpson entered into a Technology Transfer Agreement (the “Du Pingping Agreement”) with Du Pingping (“Transferor Pingping”). Transferor Pingping owns an invention patent drug composition of ansetropisimvastatin (the “Pingping Invention Patent”). Pursuant to the Du Pingping Agreement, Transferor Pingping will transfer the ownership of the Pingping Invention Patent to Helpson and provide relevant technical services. 

The aggregate transfer price as contemplated by the Agreement is $570,000 which was paid to the Transferor and his two designees upon the issuance of 2,850,000 shares of common stock of the Company at $0.20 per share based on the closing market price of the Company’s common stock as of the closing date of December 2, 2024.  The Company recorded the amount as intangible assets on the accompanying balance sheet as of the closing date. 

On February 2, 2024, Helpson entered into a Technology Transfer Agreement (the “Lihua Li Agreement”) with Lihua Li (“Transferor Li”). Transferor Li owns an invention patent of a pharmaceutical composition for treatment of psoriasis (the “Li Invention Patent”). Pursuant to the Lihua Li Agreement, Transferor Li will transfer the ownership of the Li Invention Patent to Helpson. Transferor Li or his designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application. 

The aggregate transfer price as contemplated by the Agreement is $1.365 million which was paid to the Transferor and his two designees upon the issuance of 3,000,000 shares of common stock of the Company at $0.455 per share based on the closing market price of the Company’s common stock as of the closing date.  The Company recorded the amount as intangible assets on the accompanying balance sheet as of the closing date. The value of the intangible asset will be amortized over its remaining useful life of approximately 20 years. During the ten years after the product launches to the market, if and only if the product generates profit, Helpson shall pay 10% of the net profit of the sales in cash on an annual basis to Transferor Li.

There were no service fees or profit payments paid related to the Bonier Agreement or the Technology Transfer Agreements from 2025 and 2024 for the years ended December 31, 2025 and 2024, respectively.

Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.  It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $851,609 and $447,246 for the years ended December 31, 2025 and 2024 which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period. 

Intangible assets consisted of NMPA approved medical formulas, a Utility Model Patent and eight Invention Patents as follows:

	December 31,			December 31,
	2025			2024
NMPA approved medical formulas	$	4,802,903		$	4,696,267
Technology from Bonier		1,739,737			1,701,110
Invention Patents		23,447,518			5,308,930
		29,990,158			11,706,307
Accumulated amortization		(6,246,739	)		(5,261,827	)
Net carrying amount		23,743,419			6,444,480
Intangible assets in process		335,846			250,956
	$	24,079,265		$	6,695,436

The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:

Year	Amount
2026		2,378,638
2027		2,378,638
2028		2,378,638
2029		2,378,638
2030		2,378,638
Thereafter		11,850,229
Total	$	23,743,419

Amortization expenses for the years ended December 31, 2025 and 2024 were $851,611 and $447,244, respectively.